Efficacy of suppository naproxen in prevention of pancreatitis

Efficacy of suppository naproxen in preventation of post ERCP pancreatitis in patients referred to RAZI hospital in RASHT

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105301155N14

Enrollment

324

Registered

2013-02-10

Start date

2013-02-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute pancreatitis. other acute pancreatitis

Interventions

Intervention 1: Intervention group take naproxen supp. 500 miligram just before ERCP. Intervention 2: Control group take placebo suppository.

Prevention

Placebo

Intervention group take naproxen supp. 500 miligram just before ERCP.

Control group take placebo suppository.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients over 18 years who were referred to hospital for ERCP; disorders in liver function tests; had extrahepatic cholestasis. Exclusion criteria: Acute pancreatitis in the last two weeks; history of chronic pancreatitis; a history of previous sphincterotomy; NSAID use in a week; contraindication for NSAID use such as renal failure and having allergy to the drug; peptic ulcer with recent GI bleeding; not consent to participate in this plan.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pancreatitis. Timepoint: 24 hours after ERCP. Method of measurement: Amylase serum, Patient's symptoms(nausea, vomiting and abdominal pain).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarahnaz Joukar

Gastrointestinal and Liver Disease Research Center(GLDRC)

F_Jokar@gums.ac.ir+98 13 1553 5116

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026